Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Verona Pharma (Nasdaq: VRNA) will report its fourth quarter and full year financial results for 2020 on February 25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verona Pharma (Nasdaq: VRNA) will report its fourth quarter and full year financial results for 2020 on February 25, 2021. A conference call for investors will take place at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these results and provide a corporate update. The company is known for developing therapies for respiratory diseases, notably ensifentrine, which is in Phase 3 trials for COPD treatment. The funds from a $200 million private placement in July 2020 are expected to support operations into 2023.
Positive
- Engaged in promising Phase 3 clinical program for ensifentrine, aimed at COPD treatment.
- Successfully raised $200 million through private placement in July 2020 to fund operations until 2023.
Negative
- None.
Details
News Market Reaction – VRNA
The recorded move for VRNA in the trading session of this news was +0.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and reference conference ID 7681320:
- +1-888-317-6003 for callers in the United States
- +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 90 days.
For further information, please contact:
| Verona Pharma plc | US Tel: +1-833-417-0262 UK Tel: +44 (0)20 3283 4200 |
| Victoria Stewart, Director of Communications | info@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1 212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron | |
| Optimum Strategic Communications (International Media and European Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Eva Haas / Shabnam Bashir |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.